Lin: #ampeu18 Looking for 1 mut; a stochastic process. Shows chart from #AACR18 poster 4542 https://t.co/lTU9waP3Kp
4:06am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Can go down to 0.005% at SNV, at 7-10mL plasma. 0.01% for cfDNA VAF at 90% sens. Spec at >99.5%
4:04am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Uses Streck (glass) and extraction/library prep are proprietary. Effic. is critical.
4:03am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 choice of mutants - want low background rate, spec cancer types that make sense for the type of cancer.
4:02am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Muts that not necessarily actionable; but rather the first driver + passengers (a signature, clonal mutations, ('clonotype'?)
4:01am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Their workflow: collect tumor, do WES, custom indiv-spec assays. Collect blood at 0,3,6,9 mos, extract, seq
4:00am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 For metastatic Rx - measuring effect of drugs. Signatera: looking at MRD, recurr monitoring, and Rx response
3:59am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Another Q, can you predict resp to neoadjuvant Rx? For Surveillance - imaging, symptoms often too late.
3:56am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Question - for bladder cancer, can you avoid surgery, by detecting mutations that arise early during tumor evol?
Lin: #ampeu18 Their Signatera (RUO) focus on ctDNA for monitoring, not early detection or Rx selection.
3:55am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Did work with Swanton; recent bladder work reported #AACR18 GenomeWeb writeup ($) https://t.co/5OnMK857r7
3:52am April 30th 2018 via Twitter Web Client
Lin: #ampeu18 Done over 1M NIPT; >800 empl, shows fastest growth of any NGS-based test (by quarterly vol). Many labs in EU.
C. Jimmy Lin (CSO Natera) #ampeu18 Personalized Liquid Biopsy: Applications in Colorectal, Bladder, Breast, Lung and Beyond
3:50am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Better selection, perhaps smaller fragments? Rosenfeld's work here at CRUK.
3:47am April 30th 2018 via Twitter Web Client
Q: Eval of preanalytic var's w/yield, high sensitivity? Babayan: #ampeu18 Cohen paper great step twrds screening; e… https://t.co/RNvtmptV4E
Q: Comment on CTC shedding? Babayan: #ampeu18 Theories around tissue of origin, less space from lung vs liver.
3:44am April 30th 2018 via Twitter Web Client
Q: Any rec's for collection variables for ctDNA? Babayan: #ampeu18 Goal is to come up with a std recommendation dep on the goal
Babayan: #ampeu18 CTCs for recurrence; they migrate to marrow, but what is the 'wake-up call'? Relapse may be many years later.
3:41am April 30th 2018 via Twitter Web Client
Q: Goals - what for detection? Monitoring? Resist? Babayan: #ampeu18 Depends. Early-stage: ctDNA makes sense, CTCs hard to detect.
Q: CTCs vs ctDNA? Babayan: #ampeu18 Depends on the question posed; complementary approaches.
3:38am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Impt, intensive collaboration. Founded, organizing the European Liquid Biopsy Society. Also May 3… https://t.co/uQukitP9aR
3:36am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 MicroRNAs fig from https://t.co/QhyVvD6WcQ Many kits - QIAseq, NanoString, TaqMan, Toray 3D, miRNA-Seq, miRCURY
3:34am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Transfix unpubl data on 50 spiked SK-MEL26 cells - good for 3 days, cp to EDTA for CTCs.
3:32am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Evidence: to use of CellSave for both cfDNA and CTCs. Shows unpubl data cp EDTA vs Transfix
3:31am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 EDTA vs. CellSave: blood cells preserved up to 96h. Dive's work '16 https://t.co/9rNrtzkL1w shows… https://t.co/CgfrA8dcMh
3:30am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Another set of difficulties: how about collection, preservation? PaxGene, Streck, CellSave, EDTA, Norgen, Roche...
3:29am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Cp Cellsearch and see results and variability. Used for std of analysis. Can use 1 sample, sep both MNC and plasma
3:28am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Doing diagnostic leukopheresis (DLA) for CTC enrichment. Shows ex of ring trial: DLA product div, dist.
3:27am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 Shows side-by-side chart from '16 ref https://t.co/pFoX7ieCcA Cp Cellsearch and Parsortix
3:26am April 30th 2018 via Twitter Web Client
Babayan: #ampeu18 CellSearch: CD45 exclusion marker. Independent of marker: size, or deformability: Parsortix (mis-spoke on prior tweet)
3:25am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 Lots of methods for CTC - Parsortix, Siemens, ClearCell, CellSieve are several of label-dep ones
3:24am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 40 partners; 3 working groups (CTCs, ctDNA, miRNA). https://t.co/fiWOZGnBRD Ring trials: diff comparisons
Babayan: #ampeu18 CANCER-ID - technical eval of methods, SOP est, clinical validation for NSCLC and HER2res mBC
3:22am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 Advances - points to CancerSEEK from Hopkins Almost 100% detection in Ov, https://t.co/UHbX6MNxqB
3:21am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 '17 rev EGFR mutations in cancer https://t.co/0VLIX0zy1y
3:18am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 Shows histone-wrapping, size distribution. 'Best example is FDA-cleared cobas EGFR test'
3:17am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 Cell-free ctDNA, miRNA and exosomes: low ctDNA conc 'as analytical challenge'. '16 https://t.co/79cSTzLp3a
Babyan: #ampeu18 (Anoikis resist ref https://t.co/OvoXjxXiUy ) ETM transition: impt for plasticity, readout of CTCs
3:16am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 By surviving, CTCs undergo through adaptation for specific survival. Anoikis resist, ETM transitoin, homing/invasion
3:15am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 Prognostic impact of CTCs '17 ref https://t.co/o1Remvbxmd
3:14am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 A number of CTC counts - lists 3 pubs that correlate to disease status. >5CTCs/7.5mL blood for Br Cancer and Rx
3:13am April 30th 2018 via Twitter Web Client
Babyan: #ampeu18 Fig from '17 https://t.co/68to0vDhsP A real-time snapshot of disease. Analysis of CTCs, ctDNA, even TEP
3:11am April 30th 2018 via Twitter Web Client
#ampeu18 Recent Advances in Liquid Biopsies: Challenges and Solutions Dr. Anna Babyan CANCER-ID: European Network f… https://t.co/2su0DdruNM
3:09am April 30th 2018 via Twitter Web Client
AMP Europe scientific program #ampeu18 https://t.co/7LG1OuMsbi
3:07am April 30th 2018 via Twitter Web Client
#mamsummit Mohel: You need to communicate the 'why DC' as a transplant. Connections to get foot into door. DC is by… https://t.co/ky9DSlw5CV
5:05pm April 26th 2018 via Twitter Web Client
#mamsummit Mohel: In B-school, she wanted to work for Frito-Lay in Dallas, and had no good answer 'why Dallas'.
Q: How to stand out in DC cp to other places? #mamsummit Searles: The personal connections to hiring mgr makes a difference.
5:04pm April 26th 2018 via Twitter Web Client
Q: AMZN coming to DC? Concerns? #mamsummit Molzen: optimistic med- or long-term. Demonstrating DC 'is a tech town'. Critical mass.
5:03pm April 26th 2018 via Twitter Web Client
Q: Age discrimination? #mamsummit Molzen: What sets you apart for transferable skills? Pull the story together, online co research etc.
5:02pm April 26th 2018 via Twitter Web Client
Q: About personal situation changing, going back to mktg #mamsummit Mohel: All about the story, the narrative.
5:00pm April 26th 2018 via Twitter Web Client
